Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study to assess the incidence, treatment and evolution of immune-related adverse events due to Immune checkpoint blockade therapy.

Next Previous
Trial Profile

An observational study to assess the incidence, treatment and evolution of immune-related adverse events due to Immune checkpoint blockade therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Lung cancer; Malignant melanoma; Renal cancer; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
    • 26 Nov 2018 New trial record
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top